These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 16641928

  • 21. Long-term outcome of childhood IgA nephropathy with minimal proteinuria.
    Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H, Tanaka R, Nozu K, Sako M, Iijima K, Nakanishi K, Yoshikawa N.
    Pediatr Nephrol; 2015 Dec; 30(12):2121-7. PubMed ID: 26238276
    [Abstract] [Full Text] [Related]

  • 22. Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria.
    Tan M, Li W, Zou G, Zhang C, Fang J.
    Kidney Blood Press Res; 2015 Dec; 40(2):200-6. PubMed ID: 25924707
    [Abstract] [Full Text] [Related]

  • 23. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F, Vecchio LD, Pozzi C.
    Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
    [Abstract] [Full Text] [Related]

  • 24. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C, Del Vecchio L, Locatelli F.
    G Ital Nefrol; 2002 Jan; 19(5):523-8. PubMed ID: 12439840
    [Abstract] [Full Text] [Related]

  • 25. Treatment of immunoglobulin A nephropathy.
    Schiele J, Nowack R, Julian BA, van der Woude FJ.
    Ann Med Interne (Paris); 1999 Feb; 150(2):127-36. PubMed ID: 10392261
    [Abstract] [Full Text] [Related]

  • 26. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J, Sági B, Máté J, Vas T, Kovács T.
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [Abstract] [Full Text] [Related]

  • 27. Primary IgA nephropathy in elderly patients.
    Cheungpasitporn W, Nasr SH, Thongprayoon C, Mao MA, Qian Q.
    Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
    [Abstract] [Full Text] [Related]

  • 28. The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience.
    Maixnerova D, Bauerova L, Skibova J, Rysava R, Reiterova J, Merta M, Honsova E, Tesar V.
    Nephrol Dial Transplant; 2012 Apr; 27(4):1492-8. PubMed ID: 21891776
    [Abstract] [Full Text] [Related]

  • 29. Treatment of IgA nephropathy: an update.
    Rosselli JL, Thacker SM, Karpinski JP, Petkewicz KA.
    Ann Pharmacother; 2011 Oct; 45(10):1284-96. PubMed ID: 21954446
    [Abstract] [Full Text] [Related]

  • 30. [Management of IgA nephropathy].
    Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini M.
    G Ital Nefrol; 2011 Oct; 28(6):622-32. PubMed ID: 22167613
    [Abstract] [Full Text] [Related]

  • 31. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X, Chen X, Liu S, Zhuang Y, Zhang Y.
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
    [Abstract] [Full Text] [Related]

  • 32. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F.
    J Nephrol; 2013 Jun; 26(1):86-93. PubMed ID: 22460183
    [Abstract] [Full Text] [Related]

  • 33. Comparison between patients with IgA nephropathy with minimal change disease and patients with minimal change disease.
    Li XW, Cheng SQ, Liang SS, Le WB, Zeng CH, Wang JQ, Liu ZH.
    Clin Nephrol; 2016 May; 85(5):273-81. PubMed ID: 26951969
    [Abstract] [Full Text] [Related]

  • 34. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
    Tang Y, He H, Sun W, Hu P, Chen X, Xu X.
    Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
    [Abstract] [Full Text] [Related]

  • 35. Clinical features and natural history of IgA nephropathy.
    Rychlik I, Andrassy K, Waldherr R, Zuna I, Tesar V, Jancová E, Stejskalová A, Ritz E.
    Ann Med Interne (Paris); 1999 Feb; 150(2):117-26. PubMed ID: 10392260
    [Abstract] [Full Text] [Related]

  • 36. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
    Gutiérrez E, Carvaca-Fontán F, Luzardo L, Morales E, Alonso M, Praga M.
    Nephron; 2020 Feb; 144(11):555-571. PubMed ID: 32818944
    [Abstract] [Full Text] [Related]

  • 37. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.
    D'Amico G, Napodano P, Ferrario F, Rastaldi MP, Arrigo G.
    Kidney Int; 2001 Feb; 59(2):682-92. PubMed ID: 11168950
    [Abstract] [Full Text] [Related]

  • 38. [Immunosuppressive and non-immunosuppressive agents for patients with IgA nephropathy: guideline from the Italian Society of Nephrology].
    Pozzi C, Manno C, Passerini P, Strippoli GF, Lupo A, Stratta P, Cagnoli L, Società Italiana di Nefrologia.
    G Ital Nefrol; 2007 Feb; 24 Suppl 37():S30-49. PubMed ID: 17347954
    [Abstract] [Full Text] [Related]

  • 39. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
    Tumlin JA, Hennigar RA.
    Semin Nephrol; 2004 May; 24(3):256-68. PubMed ID: 15156530
    [Abstract] [Full Text] [Related]

  • 40. Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.
    Rivedal M, Haaskjold YL, Eikrem Ø, Bjørneklett R, Marti HP, Knoop T.
    BMC Nephrol; 2024 Jan 29; 25(1):42. PubMed ID: 38287343
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.